The Endocrine team comprises 2 products, Ngenla and Genotropin. Ngenla is a once-weekly pediatric growth hormone deficiency (pGHD) therapy that launched in June 2023 and is poised to become the anchor product of the franchise. Genotropin was the first product approved to treat pGHD in 1987. Approximately 1 in 4,000 US children are affected by pGHD and can result in physical, emotional, and social burden for the patients and their families. Current therapies (including Genotropin) require patients to commit to daily injections, leaving patients tethered to a strict injection schedule, which can impact quality of life and lead to suboptimal adherence, which affects their growth trajectory. Ngenla is among a new class of pGHD therapies that can offer patients similar growth to daily therapy, but with only 1 injection a week. The Senior Manager, Access and Patient Marketing will be a key contributor to the Endocrine brand team, leading initiatives that support patient access and engagement across Ngenla and Genotropin, with a strategic emphasis on Ngenla. This role will collaborate cross-functionally to ensure seamless execution of access and patient support strategies, while also managing creative development and agency partnerships. The ideal candidate will bring a patient-first mindset, strong project management skills, and a passion for improving the treatment journey for pediatric patients and their families. This role will report to the US Endocrine Marketing Lead; however, will collaborate closely with the US Endocrine Access & Patient Solutions Director and the Endocrine Consumer Lead.